Multidrug-resistant tuberculosis (MDR-TB) is widespread globally with almost half a million cases documented in 2014. Although rare in European countries, the risks posed by the current migrant crisis makes MDR-TB an important and urgent public health priority. A study just published in Clinical Microbiology and Infection documents that the rate of infection with MDR-TB is higher among migrants than in the general population, particularly in those born outside Europe and in those forced to leave their home country as asylum seekers and refugees.
The data reviewed by Hargreaves, et al. shows that 100 percent of the MDR-TB cases diagnosed in Austria, The Netherlands and Norway occurred in migrants to those countries. A high proportion of MDR-TB cases were also apparent in migrants to other European states – 90 percent in the UK, 89 percent in France, 87 percent in Italy and 94 percent in Germany.
Migrants are at higher risk of contracting MDR-TB both in their country of origin, because of the breakdown of their own healthcare system, and after arriving in Europe, because of destitution, homelessness, overcrowding in refugee camps or incarceration. A significant proportion of MDR-TB cases in migrants result from reactivation of latent infection.
Screening, diagnosis and treatment is available for all forms of TB, including active MDR-TB. However, this is rarely accessed by migrants due to restrictions set by healthcare systems or to fear on the part of the migrants that becoming known to the authorities might result in deportation back to the violence they have fled.
“Although there is evidence that transmission of TB from migrants to the general population is low – it predominantly occurs between migrants – there is a risk of transmission for both migrants and the native population,” notes professor Jon S. Friedland of the International Health Unit, Infectious Diseases & Immunity, Imperial College London, UK, who is senior author of the study. “There is a human rights obligation to improve the diagnosis, treatment and prevention of MDR-TB in migrants.”
After analyzing the content of several studies on MDR-TB, the paper recommends a multi-faceted strategy to improve access to services, more consistent pan-European protocols for screening and treatment, and further research to document the level of MDR-TB infection in the European migrant population.
Detailed recommendations include:
- Changing healthcare policies so that there are fewer barriers to migrants with respect to TB screening, diagnosis and treatment. This would not be granting ‘favors’ to migrants; it would be a sound public health policy to reduce the risk of MDR-TB transmission to other migrants and the wider population.
- Providing better healthcare generally to migrant populations in individual host countries.
- Developing financial and social support mechanisms for migrants who are diagnosed with MDR-TB.
- Drawing up and adopting pan-European evidence-based guidelines for screening methods and how to implement them in the migrant populations.
- Research is also required to develop a reliable diagnostic test that can detect latent MDR-TB and to predict the risk of disease re-activation.
- More evidence that can be used to develop guidelines on how to manage MDR-TB more effectively in migrant populations across Europe is needed
Source: ESCMID
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
Sharps Safety Starts with Us: Why Infection Preventionists Must Lead the Charge
July 28th 2025Sharps injuries remain a silent but serious threat in health care that infection preventionists are uniquely equipped to confront. With underreporting widespread and safety devices underused, it’s time for IPs to step into a leadership role, using their expertise in systems thinking, education, and policy to build a culture where staff protection is as prioritized as patient care.
Flawed From the Start: Why Many IFUs for Surgical Instruments Fail in Real-World Sterile Processing
July 23rd 2025At the 2025 HSPA Annual Conference & Expo, Cori L. Ofstead, MSPH, highlighted critical flaws in manufacturers’ instructions for use (IFUs) for orthopedic and neurosurgical instruments. From contradictory directions to unrealistic cleaning expectations, these IFUs often fail under real-world conditions, jeopardizing both patient safety and sterile processing workflows.
Pathogen Pulse: Facilities Need the SPD, Yersinia Enterocolitica Outbreak, and More
July 22nd 2025From unsterilized surgical tools in Colorado to a years-long methicillin-resistant Staphylococcus aureus (MRSA) outbreak in Virginia and a surging measles crisis in Canada, recent headlines reveal the fragile front lines of infection prevention and the high stakes when systems fail.
Telemedicine's Transformative Role in PPE Distribution and Sterile Equipment Management
July 22nd 2025In an era defined by digital transformation and post-pandemic urgency, telemedicine has evolved beyond virtual visits to become a vital infrastructure for delivering personal protective equipment (PPE) and managing sterile supplies. By enabling real-time forecasting, remote quality control, and equitable distribution, telemedicine is revolutionizing how health care systems protect both patients and providers.